Type 2 Diabetes
Artikler
Need to identify risk of developing autoimmune type 1 diabetes? Test for autoantibodies!
Anti-islet autoantibodies that target proteins associated with beta-cells serve as biomarkers of autoimmune type 1 diabetes (T1D) development.1 The number of detectable autoantibodies through screening correlates with risk of developing autoimmune T1D.2 Assays for detecting autoimmune T1D have shown high sensitivity and specificity.3,4
Autoimmune Type 1 Diabetes
The Type 1 Diabetes (T1D) field is evolving.
Recognition of the presymptomatic stages in T1D is growing.1-4
The clinical benefits of early detection of T1D are being highlighted.3-4 Programmes focusing on early detection through testing and screening for presymptomatic autoimmune T1D are increasingly offered to risk populations and the general population.1,2
Glycaemic Targets and Vascular Complications in Type 2 Diabetes: What Are the Thresholds?
Summary of Zoungas S, et al. Diabetologia. 2012;55:636–643.
How Does Glycaemic Control Impact Complications in Type 2 Diabetes?
Summary of The UK Prospective Diabetes Study (UKPDS).
Why is Glycaemic Control in Type 2 Diabetes Still a Challenge?
Summary of Aschner P, et al. Diabetologia. 2020;63(4):711-721.
Is Glycemic Control the Key to Preventing Long-term Complications in Type 2 Diabetes?
(Based on the study: Stratton IM, et al. BMJ. 2000;321(7258):405-12).